GlassScriptPhysician profile
Vandana Long
NPI 1831119189
$2,583.23
in general payments reported to CMS, 2019-2025
27 companies · $948 in 2025
The $948 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $47.78 · 2021: $83.69 · 2022: $202 · 2023: $305 · 2024: $700 · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,944 · Education: $9.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,944.12 |
| Education | $9.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $697.57 | 2021-2025 | |
| Janssen Biotech, INC. | $248.37 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $202.34 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $192.10 | 2020-2025 | Eohilia, Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.46 | 2023-2025 | Xifaxan, Plenvu |
| Medical Device Business Services, INC. | $120.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $120.00 | 2024 | |
| Madrigal Pharmaceuticals | $101.80 | 2025 | Rezdiffra |
| Celgene Corporation | $98.96 | 2023-2024 | Zeposia |
| Genzyme Corporation | $87.61 | 2025 | |
| Qol Medical, LLC | $74.81 | 2019-2023 | Sucraid |
| Merck Sharp & Dohme LLC | $63.85 | 2023-2024 | Dificid |
| Gilead Sciences, INC. | $53.78 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $48.19 | 2022-2023 | Rebyota |
| Ardelyx, INC. | $46.94 | 2024-2025 | Ibsrela |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $45.85 | 2024-2025 | Voquezna |
| Micro-Tech Endoscopy USA, INC. | $44.65 | 2024-2025 | Sureclip, Dilation Balloons |
| Olympus America INC. | $29.18 | 2019 | |
| Mallinckrodt Hospital Products INC. | $28.94 | 2025 | Terlivaz |
| Lilly USA, LLC | $27.91 | 2025 | Omvoh |
| Daiichi Sankyo INC. | $24.34 | 2021 | |
| Novo Nordisk INC | $23.60 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $17.36 | 2025 | Givlaari |
| Shionogi INC | $17.08 | 2019 | |
| Intercept Pharmaceuticals, INC. | $16.64 | 2022 | |
| Medtronic, INC. | $14.66 | 2023 | Gi Genius |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vandana Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.